Hyperthermia / selectivity Cancer Research Results

HPT, Hyperthermia: Click to Expand ⟱
Features:
Mild Hyperthermia (Approximately 39°C to 41°C
Pathways and Effects:
-Heat Shock Protein (HSP) Induction: Mild heat stress triggers the production of HSPs (e.g., HSP70, HSP90) that help cells cope with stress, which can sometimes provide a transient protective effect. However, these proteins can also act as immunomodulators.
-Modulation of the Immune System: Mild hyperthermia can enhance dendritic cell activation and improve antigen presentation, leading to the stimulation of anti-tumor immune responses.
-Vasodilation: Increased blood flow and improved oxygenation can sensitize tumors to radiation therapy and certain chemotherapeutics.

Moderate Hyperthermia (Approximately 41°C to 43°C)
Pathways and Effects:
-Enhanced Cytotoxicity: At temperatures in this range, tumor cells become more vulnerable to radiation and some chemotherapeutic agents. This is partly due to the inhibition of DNA repair pathways.
-Increased Permeability: Moderate heat can increase the permeability of cellular membranes, aiding in drug delivery and the uptake of chemotherapeutic agents.
-Induction of Apoptosis: Elevated temperatures can trigger apoptotic signaling pathways in cancer cells, sometimes in conjunction with other therapies.

High Hyperthermia / Thermal Ablation (Approximately 43°C to 50°C and above)
Pathways and Effects:
-Direct Cytotoxicity: High temperatures can lead to protein denaturation, membrane disruption, and direct cell death.
-Coagulative Necrosis: Sustained high temperatures cause irreversible cell injury leading to necrosis of tumor tissues.
-Vascular Damage: Hyperthermia in this range can damage tumor vasculature, reducing blood supply and indirectly causing tumor cell death.
-Enhanced Immune Response: Although high temperatures can cause immediate cell death, the release of tumor antigens and damage-associated molecular patterns (DAMPs) can stimulate an anti-tumor immune response


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Proteotoxic stress / protein denaturation Misfolded protein burden ↑; proteostasis overload ↑ Heat stress response (tolerance higher if well-perfused) P, R Core physical stressor Direct heat disrupts protein folding and complex stability; tumors can be more vulnerable due to baseline stress and poor perfusion.
2 Heat Shock Response (HSF1 → HSPs) HSP70/HSP90 ↑; stress tolerance ↑ (can be protective) HSP induction ↑ (protective) R, G Adaptive survival program HSP induction is a major adaptation; can blunt repeated heat exposures and is a key reason scheduling matters.
3 DNA damage repair inhibition / radiosensitization HR repair ↓; DNA repair capacity ↓ (reported) ↔ (tissue-dependent) R Sensitization to radiation Hyperthermia can impair DNA repair processes (notably homologous recombination), increasing radiation effectiveness when timed appropriately.
4 Tumor perfusion / oxygenation changes Perfusion ↑ (often) → oxygenation ↑; hypoxia ↓ (context) Perfusion ↑ P, R Microenvironment modulation Improved perfusion can increase oxygenation (helping radiotherapy) and improve delivery of some drugs; effects depend on local vascular state.
5 Cell membrane / cytoskeleton disruption Membrane permeability ↑; cytoskeletal stress ↑ ↔ / injury possible at higher exposures P, R Physical cell stress Heat can increase permeability and alter membrane trafficking; contributes to drug uptake in some settings.
6 Intrinsic apoptosis / necrosis (dose-dependent) Apoptosis ↑ or necrosis ↑ at higher thermal dose Collateral injury risk if overdosed R, G Direct cytotoxicity (thermal dose dependent) At moderate hyperthermia, sensitization dominates; at higher thermal dose, direct cell killing becomes more prominent.
7 Immune activation / DAMP release (ICD-like signals) DAMPs ↑; antigen presentation ↑ (reported) — G Immune support Heat stress and tumor cell damage can release DAMPs and promote immune visibility; strength varies by regimen and tumor type.
8 Vascular effects (edema, vessel damage) at higher dose Vascular injury ↑ at higher thermal dose Normal tissue injury risk ↑ R, G Toxicity / local control effects At higher temperatures or prolonged exposure, vascular damage contributes to tumor control but increases normal tissue risk.
9 Chemo-sensitization (drug delivery + stress synergy) Drug uptake ↑; cytotoxic synergy ↑ (reported) Systemic toxicity may ↑ depending on regimen R, G Combination leverage Heat can potentiate some agents (e.g., platinum drugs) and improve delivery; regimen-specific.
10 Thermal dose / parameter dependence (time×temp) Outcome depends on temperature, duration, targeting, and timing vs RT/chemo Safety depends on precision and monitoring — Translation constraint Hyperthermia is highly dose-dependent; “too little” yields little sensitization, “too much” increases burns/necrosis risk.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (direct heat stress; perfusion/permeability shifts begin)
  • R: 30 min–3 hr (HSP induction; DNA repair suppression; apoptosis initiation)
  • G: >3 hr (phenotype outcomes: immune effects, sensitization results, tissue injury)
selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
1674- PBG,  SDT,  HPT,    Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells
- in-vitro, PC, PANC1 - in-vitro, Nor, H6c7
tumCV↓, ROS↑, eff↑, Dose∅, selectivity↑, MMP↓, mtDam↑, cl‑PARP↑, p‑ERK↓, p‑JNK↑, p‑p38↑, eff↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   mtDam↑, 1,  

Cell Death ⓘ

p‑JNK↑, 1,   p‑p38↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose∅, 1,   eff↓, 1,   eff↑, 1,   selectivity↑, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: selectivity, selectivity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:98  Target#:1110  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page